CN102892432A - 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 - Google Patents
用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 Download PDFInfo
- Publication number
- CN102892432A CN102892432A CN201180024138XA CN201180024138A CN102892432A CN 102892432 A CN102892432 A CN 102892432A CN 201180024138X A CN201180024138X A CN 201180024138XA CN 201180024138 A CN201180024138 A CN 201180024138A CN 102892432 A CN102892432 A CN 102892432A
- Authority
- CN
- China
- Prior art keywords
- antibody
- neovascularization
- antibody according
- disease
- conservative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710912201.2A CN107648605A (zh) | 2010-05-28 | 2011-05-27 | 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34927110P | 2010-05-28 | 2010-05-28 | |
| US61/349,271 | 2010-05-28 | ||
| PCT/EP2011/058777 WO2011147984A1 (en) | 2010-05-28 | 2011-05-27 | Anti-cd160 specific antibodies for the treatment of eye disorders based on neoangiogenesis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710912201.2A Division CN107648605A (zh) | 2010-05-28 | 2011-05-27 | 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102892432A true CN102892432A (zh) | 2013-01-23 |
Family
ID=44276158
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180024138XA Pending CN102892432A (zh) | 2010-05-28 | 2011-05-27 | 用于治疗基于新血管生成的眼部疾病的抗-cd160特异性抗体 |
| CN201710912201.2A Pending CN107648605A (zh) | 2010-05-28 | 2011-05-27 | 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710912201.2A Pending CN107648605A (zh) | 2010-05-28 | 2011-05-27 | 用于治疗基于新血管生成的眼部疾病的抗‑cd160特异性抗体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9045544B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2575881B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5990511B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101847572B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN102892432A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112012030318A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2796312C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2575881T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2606627T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2575881T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011147984A1 (cg-RX-API-DMAC7.html) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110121508A (zh) * | 2016-10-25 | 2019-08-13 | 法国国家健康和医学研究院 | 与cd160跨膜同种型结合的单克隆抗体 |
| CN110381999A (zh) * | 2017-01-06 | 2019-10-25 | 埃尔萨里斯生物技术公司 | 结合人cd160的化合物及其用途 |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10561707B2 (en) * | 2013-09-08 | 2020-02-18 | Technion Research And Development Foundation Ltd. | Semaphorin 3C variants, compositions comprising said variants and methods of use thereof in treating eye diseases |
| WO2015168619A1 (en) * | 2014-05-02 | 2015-11-05 | Mayo Foundation For Medical Education And Research | Individualized treatment of eye disease |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| JP2020532586A (ja) * | 2017-08-31 | 2020-11-12 | シンガポール ヘルス サービシーズ プライベート リミテッド | 網膜血管性疾患の処置のためのangio−3 |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230073132A1 (en) * | 2019-12-31 | 2023-03-09 | Medstar Health, Inc. | Anti-cd 160 binding molecules for treating diseases |
| EP4225792A1 (en) | 2020-10-08 | 2023-08-16 | Affimed GmbH | Trispecific binders |
| JP2024529381A (ja) | 2021-07-30 | 2024-08-06 | アフィメド ゲーエムベーハー | デュプレックスボディ |
| EP4587122A1 (en) | 2022-09-15 | 2025-07-23 | Avidicure IP B.V. | Multispecific antigen binding proteins for stimulating nk cells and use thereof |
| WO2025191136A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof |
| WO2025191133A1 (en) | 2024-03-15 | 2025-09-18 | Avidicure Ip B.V. | Il-21 muteins, fusion proteins comprising the same and uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015886A1 (en) * | 2004-08-09 | 2006-02-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| EP2186529A2 (en) * | 2007-08-07 | 2010-05-19 | Asociación Civil De Estudios Superiores | Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| CA2117477C (en) | 1992-12-11 | 2001-06-12 | Peter S. Mezes | Multivalent single chain antibodies |
| AU5253898A (en) | 1996-11-12 | 1998-06-03 | Dana-Farber Cancer Institute | Recombinant by55 and nucleic acids encoding same |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| FR2794977B1 (fr) * | 1999-06-18 | 2003-10-31 | Commissariat Energie Atomique | Utilisation de compositions contenant des formes solubles d'hla-g dans le traitement de pathologies inflammatoires de la peau, et leur procede d'obtention |
| CA2622312A1 (en) * | 2006-01-30 | 2007-08-02 | (Osi) Eyetech, Inc. | Combination therapy for the treatment of neovascular disorders |
-
2011
- 2011-05-27 EP EP11728594.0A patent/EP2575881B1/en active Active
- 2011-05-27 CN CN201180024138XA patent/CN102892432A/zh active Pending
- 2011-05-27 US US13/697,699 patent/US9045544B2/en active Active
- 2011-05-27 PL PL11728594T patent/PL2575881T3/pl unknown
- 2011-05-27 CA CA2796312A patent/CA2796312C/en active Active
- 2011-05-27 DK DK11728594.0T patent/DK2575881T3/en active
- 2011-05-27 BR BR112012030318A patent/BR112012030318A2/pt not_active Application Discontinuation
- 2011-05-27 WO PCT/EP2011/058777 patent/WO2011147984A1/en not_active Ceased
- 2011-05-27 JP JP2013511702A patent/JP5990511B2/ja not_active Expired - Fee Related
- 2011-05-27 ES ES11728594.0T patent/ES2606627T3/es active Active
- 2011-05-27 CN CN201710912201.2A patent/CN107648605A/zh active Pending
- 2011-05-27 KR KR1020127034345A patent/KR101847572B1/ko not_active Expired - Fee Related
-
2015
- 2015-06-02 US US14/728,253 patent/US10208124B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015886A1 (en) * | 2004-08-09 | 2006-02-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2 |
| EP2186529A2 (en) * | 2007-08-07 | 2010-05-19 | Asociación Civil De Estudios Superiores | Synergic pharmaceutical composition, useful for inhibiting corneal and retinal neovascularization (angiogenesis), and in other organs, in a human being or animal |
Non-Patent Citations (1)
| Title |
|---|
| PIERRE FONS等: "Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells", 《BLOOD》, vol. 108, no. 8, 29 June 2006 (2006-06-29), pages 2608 - 2615, XP002530233, DOI: doi:10.1182/blood-2005-12-019919 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110121508A (zh) * | 2016-10-25 | 2019-08-13 | 法国国家健康和医学研究院 | 与cd160跨膜同种型结合的单克隆抗体 |
| CN110381999A (zh) * | 2017-01-06 | 2019-10-25 | 埃尔萨里斯生物技术公司 | 结合人cd160的化合物及其用途 |
| CN110381999B (zh) * | 2017-01-06 | 2023-12-01 | 埃尔萨里斯生物技术公司 | 结合人cd160的化合物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150344572A1 (en) | 2015-12-03 |
| CN107648605A (zh) | 2018-02-02 |
| DK2575881T3 (en) | 2017-01-09 |
| US9045544B2 (en) | 2015-06-02 |
| JP2013528607A (ja) | 2013-07-11 |
| JP5990511B2 (ja) | 2016-09-14 |
| KR20130086548A (ko) | 2013-08-02 |
| EP2575881B1 (en) | 2016-09-14 |
| CA2796312A1 (en) | 2011-12-01 |
| US10208124B2 (en) | 2019-02-19 |
| KR101847572B1 (ko) | 2018-05-24 |
| US20130122006A1 (en) | 2013-05-16 |
| CA2796312C (en) | 2020-11-03 |
| WO2011147984A1 (en) | 2011-12-01 |
| ES2606627T8 (es) | 2017-06-09 |
| ES2606627T3 (es) | 2017-03-24 |
| BR112012030318A2 (pt) | 2017-06-20 |
| EP2575881A1 (en) | 2013-04-10 |
| PL2575881T3 (pl) | 2018-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10208124B2 (en) | Anti-CD160 specific antibodies for the treatment of eye disorders based on neoangiogenesis | |
| Chakravarthy et al. | Phase I trial of anti–vascular endothelial growth factor/anti-angiopoietin 2 bispecific antibody RG7716 for neovascular age-related macular degeneration | |
| Zhang et al. | A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration | |
| US9555126B2 (en) | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of B-cell malignancies symptoms | |
| TW201522378A (zh) | 用於治療人類癌症的特異性抗cd38抗體 | |
| JP4857259B2 (ja) | 癌細胞増殖を阻害するための抗α5β1抗体の使用 | |
| TWI844571B (zh) | 使用抗血管內皮生長因子(vegf)抗體與抗組織因子(tf)抗體-藥物共軛體之組合以治療癌症之方法 | |
| KR20180134367A (ko) | 암의 치료에서 항-cd47 제제의 치료적으로 효과적인 용량을 결정하고 달성하는 방법 | |
| EA037551B1 (ru) | Применение молекул, связывающих семафорин-4d, для лечения атеросклероза | |
| AU2016241499A1 (en) | Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused | |
| TW200815468A (en) | Use of organic compounds | |
| TWI923686B (zh) | 補體c3抗原結合蛋白 | |
| CN114728061A (zh) | 治疗糖尿病性视网膜病变的方法和组合物 | |
| WO2022201084A1 (en) | Methods for treating ocular diseases | |
| CN113645994A (zh) | 使用色素上皮衍生因子(pedf)治疗疾病的方法 | |
| Chabot et al. | A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor | |
| US9463217B1 (en) | Methods and pharmaceutical compositions for treatment of retinal occlusion | |
| JP7189878B2 (ja) | ヒトcd160を結合する結合物及びその使用 | |
| RU2843013C1 (ru) | Способы и композиции для лечения диабетической ретинопатии | |
| JP2007510738A (ja) | CD11d(α−d)インテグリンに特異的に結合する組成物を使用した慢性疼痛を処置する方法 | |
| EP3538553A1 (en) | Anti-secretogranin iii (scg3) antibodies and uses thereof | |
| TW202532435A (zh) | 治療新生血管性眼疾之方法 | |
| WO2023160517A1 (zh) | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 | |
| WO2025081130A1 (en) | Use of anti-asc antibody in the treating of ocular disorders | |
| TW202438525A (zh) | Lair-1促效性抗體及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20130123 |